Key Market Indicator:
In this news category you will find information from and about companies, organizations, institutions, products of all kinds and in a broad spectrum. To get a quick overview of current trends and developments, it's worth visiting daily.
DE000A1EWVY8
Thu, 03.11.2022
Formycon AG
Press Release // November 3, 2022
Broad-acting antiviral SARS-CoV-2 drug FYB207 shows longer half-life and improved efficacy through optimized molecular design in preclinical studies
Protein and glycoengineering improve pharmacokinetics and efficacy
Half-life of more than 14 days comparable to the bioavailability of an antibody
Reduction of vi [ … ]
Fri, 28.10.2022
Formycon AG
Press Release // October 28, 2022
Formycon reports final figures for the first half of 2022
Consolidated reporting for the first time under IFRS (International Financial Reporting Standards)
Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20,1 million) as well as EBITDA of Euro -7,6 million (H1/2021 IFRS: Euro -9,7 million) and operati [ … ]
Fri, 28.10.2022
Formycon AG
Press Release // October 28, 2022
Formycon reports final figures for the first half of 2022
Consolidated reporting for the first time under IFRS (International Financial Reporting Standards)
Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20,1 million) as well as EBITDA of Euro -7,6 million (H1/2021 IFRS: Euro -9,7 million) and operati [ … ]
Mon, 19.09.2022
Formycon AG
Press Release // September 19, 2022
Formycon publishes details of a previously undisclosed pipeline project – FYB206 is a biosimilar candidate for Keytruda®* (pembrolizumab)
Positioning in the field of immuno-oncology with the biosimilar candidate FYB206
Addressable market size expected to be well above USD 20 billion after patent expi [ … ]
Mon, 19.09.2022
Formycon AG
Press Release // September 19, 2022
Formycon publishes details of a previously undisclosed pipeline project – FYB206 is a biosimilar candidate for Keytruda®* (pembrolizumab)
Positioning in the field of immuno-oncology with the biosimilar candidate FYB206
Addressable market size expected to be well above USD 20 billion after patent expi [ … ]
Tue, 06.09.2022
Formycon AG
Press Release // September 6, 2022
Formycon publishes preliminary figures for the first half of 2022
Reporting at Group level for the first time under IFRS (International Financial Reporting Standards)
Preliminary figures overall in line with forecast: Preliminary Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20.3 million) and prel [ … ]
Tue, 06.09.2022
Formycon AG
Press Release // September 6, 2022
Formycon publishes preliminary figures for the first half of 2022
Reporting at Group level for the first time under IFRS (International Financial Reporting Standards)
Preliminary figures overall in line with forecast: Preliminary Group turnover of Euro 17.6 million (H1/2021 IFRS: Euro 20.3 million) and prel [ … ]
Mon, 29.08.2022
Formycon AG
Press Release, August 29, 2022
European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2
Munich, Amsterdam, Zug – Formycon AG (“Formycon”), Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorizat [ … ]
Mon, 29.08.2022
Formycon AG
Press Release, August 29, 2022
European Commission approves FYB201/Ranivisio®1 (Ranivisio - Ranibizumab), a biosimilar to Lucentis®2
Munich, Amsterdam, Zug – Formycon AG (“Formycon”), Polpharma Biologics Group BV (“Polpharma Biologics”) and Bioeq AG (“Bioeq”) jointly announce that the European Commission (“EC”) has granted marketing authorizat [ … ]
Tue, 16.08.2022
Formycon AG
Press Release // August 16, 2022
Formycon’s Biosimilar Ustekinumab Candidate FYB202 Shows Comparable Efficacy to Reference Product Stelara®* in Phase III Study
VESPUCCI study demonstrates the comparable efficacy of FYB202 to the reference product Stelara® in patients with moderate to severe psoriasis vulgaris (plaque psoriasis)
Primary Effic [ … ]